FDA approves sofosbuvir/ledipasvir and sofosbuvir for children aged 12 to 17
26 June 2017. Related: Hepatitis coinfection, Paediatric care Comment
Comment
HIV Treatment Bulletin
Hepatitis coinfection
Cochrane review of HCV treatment misses real issues of access to care
26 June 2017. Related: Hepatitis coinfection, Treatment access Comment
Other selections and webcasts
24 April 2017. Related: Antiretrovirals, Conference reports, Cure research, Hepatitis coinfection, Opportunistic infections and complications , BHIVA 23rd Liverpool 2017
Tenofovir alafenamide (TAF) approved in US to treat hepatitis B with EU set to follow
29 November 2016. Related: Hepatitis coinfection
2016 hepatitis C virus (HCV) update
14 July 2016. Related: Hepatitis coinfection, Pipeline report, Special reports
New HBV drugs and non-viral liver disease in HIV positive people
1 June 2016. Related: Basic science and immunology, Conference reports, Hepatitis coinfection , BHIVA 22nd Manchester 2016
High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries
1 June 2016. Related: Conference reports, Hepatitis coinfection, Other news, Treatment access , EASL Barcelona 2016
Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries
1 June 2016. Related: Antiretrovirals, Conference reports, Hepatitis coinfection , EASL Barcelona 2016
Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV
1 June 2016. Related: Conference reports, Hepatitis coinfection , CROI 23 (Retrovirus) 2016
NICE approves ombitasvir, paritaprevir, ritonavir with or without dasabuvir to treat adult HCV
1 February 2016. Related: Hepatitis coinfection
NICE approves daclatasvir to treat adult HCV
1 February 2016. Related: Hepatitis coinfection
Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23
1 December 2015. Related: Conference reports, Hepatitis coinfection, Treatment access , EACS 15 Barcelona 2015
NICE decision on ledipasvir/sofosbuvir for chronic HCV
1 December 2015. Related: Hepatitis coinfection
Sofosbuvir/velpatasvir submitted to US FDA for HCV genotype 1-6
1 December 2015. Related: Hepatitis coinfection
US indication for ledipasvir/sofosbuvir expanded
1 December 2015. Related: Hepatitis coinfection
Protection against flu but not HBV in vaccinated perinatally HIV-infected children
1 October 2015. Related: Conference reports, Hepatitis coinfection, Paediatric care , ICAAC 55th San Diego 2015
Gilead to provide free hepatitis drugs to treat all people liviing with hepatitis C in Iceland
1 October 2015. Related: Hepatitis coinfection
Australian doctors advice for buying generic sofosbuvir for HepC
1 October 2015. Related: Hepatitis coinfection, Treatment access
Comprehensive review of DAA research at EASL
1 August 2015. Related: Hepatitis coinfection
New Drugs, New Strategies: Conquering Hepatitis C with Direct-Acting Antivirals
17 July 2015. Related: Hepatitis coinfection, Pipeline report, Special reports
Sofosbuvir access: new patent challenges to sofosbuvir
1 June 2015. Related: Hepatitis coinfection, Treatment access
Summary of the pre-conference clinical course
29 January 2015. Related: Conference reports, Hepatitis coinfection , Five Nations Conference on HIV and Hepatitis
Hepatitis C drug access: Europe is the new Africa
29 January 2015. Related: Conference reports, Hepatitis coinfection, Treatment access , Five Nations Conference on HIV and Hepatitis
India rejects Gilead’s patent application for sofosbuvir
29 January 2015. Related: Hepatitis coinfection, Treatment access
Hepatitis C combination from AbbVie licensed in the UK: ombitasvir/paritaprevir/ritonavir (Viekirax) and dasabuvir (Exviera)
29 January 2015. Related: Hepatitis coinfection
US activists called on Gilead to set a per-treatment price for sofosbuvir/ledipasvir
1 December 2014. Related: Hepatitis coinfection
Only 10% of veterans with HCV or HCV/HIV in the US treated for HCV
1 October 2014. Related: Conference reports, Hepatitis coinfection , ICAAC 54th Washington 2014
Daclatasvir approved in EU for HCV genotypes 1-4
1 October 2014. Related: Hepatitis coinfection
CHMP gives positive opinion to approve coformulated sofosbuvir/ledipasvir
1 October 2014. Related: Hepatitis coinfection
European activists protest at meeting of European Health Ministers for access to new HCV drugs
1 October 2014. Related: Hepatitis coinfection
US Senate investigate Gilead for sofosbuvir price: potential to bankrupt Federal healthcare and add $300 annually to every American insurance premium for the next five years
1 August 2014. Related: Hepatitis coinfection
Hepatitis C pipeline: BONANZA! The gold rush is under way
19 July 2014. Related: Hepatitis coinfection, Pipeline report, Special reports
Global update: hepatitis C treatment activism
19 July 2014. Related: Hepatitis coinfection, Pipeline report, Special reports, Treatment access
WHO launch treatment guidelines for hepatitis C (2014)
27 May 2014. Related: Conference reports, Guidelines, Hepatitis coinfection , EASL 49 London 2014
Sexually transmitted HCV in HIV positive and negative gay men
27 May 2014. Related: Conference reports, Hepatitis coinfection , BHIVA 20th Liverpool 2014
Annual HCV testing and use of core antigen to reduce costs and increase diagnosis during acute HCV
27 May 2014. Related: Conference reports, Hepatitis coinfection , BHIVA 20th Liverpool 2014
EMA fast-track sofosbuvir/ledipasvir FDC for hepatitis C
27 May 2014. Related: Hepatitis coinfection
Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting
24 March 2014. Related: Hepatitis coinfection
New treatments for HCV: strategies for achieving universal access
24 March 2014. Related: Hepatitis coinfection
EASL update guidelines for treatment of hepatitis C (2013)
1 February 2014. Related: Hepatitis coinfection
Sofosbuvir approved in the US and Europe for HCV genotypes 1-6
1 February 2014. Related: Hepatitis coinfection
Simeprevir approved in the US
1 February 2014. Related: Hepatitis coinfection
Fair Pricing Coalition criticises cost of new HCV drugs
1 February 2014. Related: Hepatitis coinfection
Boehringer Ingelheim stops development of deleobuvir for HCV
1 February 2014. Related: Hepatitis coinfection
EU recommends approval of sofosbuvir for HCV
1 December 2013. Related: Hepatitis coinfection
Compassionate use of declatasvir with sofosbuvir for people in urgent need of HCV treatment
1 December 2013. Related: Hepatitis coinfection
CID supplement on HCV and injecting drug users: free online issue
1 October 2013. Related: Hepatitis coinfection, Injecting drug users, On the web
Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes
25 July 2013. Related: Conference reports, Hepatitis coinfection, Treatment access , IAS 7 Kuala Lumpur 2013
Executive summary and research policy recommendations
30 June 2013. Related: Antiretrovirals, Diagnostics, Hepatitis coinfection, Pipeline report, Special reports, TB coinfection, Treatment strategies
Hepatitis C drug development catapults onward
30 June 2013. Related: Hepatitis coinfection, Pipeline report, Special reports
Low- and middle-income countries defuse hepatitis C
30 June 2013. Related: Hepatitis coinfection, Pipeline report, Special reports, Virology
Dramatic advances at CROI for HCV treatment: telaprevir, boceprevir, faldaprevir, sofosbuvir, ABT-450, ABT-267, ABT-333 and ledipasvir
29 May 2013. Related: Conference reports, Hepatitis coinfection , CROI 20 (Retrovirus) 2013
HIV/HCV coinfection: early glimpses of an interferon-free future and EuroSIDA incidence data
1 December 2012. Related: Conference reports, Hepatitis coinfection , HIV 11 Glasgow 2012
Cure rates with pipeline HCV drugs: reports from AASLD
1 December 2012. Related: Conference reports, Hepatitis coinfection , 63rd AASLD Boston 2012
Hepatitis C coinfection studies
1 April 2012. Related: Conference reports, Hepatitis coinfection , CROI 19 (Retrovirus) 2012
FDA approve boceprevir (Victrelis) for HCV
1 August 2011. Related: Hepatitis coinfection
FDA approve telaprevir (Incivek) to treat hepatitis C
1 August 2011. Related: Hepatitis coinfection
FDA supplemental information about using boceprevir and telaprevir
1 August 2011. Related: Hepatitis coinfection
The hepatitis C treatment pipeline
14 July 2011. Related: Hepatitis coinfection
First results from telaprevir in HIV/HCV coinfection
1 April 2011. Related: Antiretrovirals, Conference reports, Hepatitis coinfection , CROI 18 (Retrovirus) 2011
Hepatitis B drugs in development
1 July 2010. Related: Hepatitis coinfection
Hepatitis C treatment pipeline
1 July 2010. Related: Hepatitis coinfection
Route of HCV transmission in HIV-positive gay men is unlikely to be from semen
1 June 2010. Related: Conference reports, Hepatitis coinfection , BHIVA 16th Manchester 2010
Hepatitis studies: IL28B genetics, HCV survival, FibroScan in acute HCV, MSM reinfection and responses to transplantation
1 June 2010. Related: Conference reports, Hepatitis coinfection , CROI 17 (Retrovirus) 2010
The HCV pipeline efficacy and side effect of compounds in Phase 3 studies
20 February 2010. Related: Conference reports, Hepatitis coinfection , Lipodystrophy Workshop (IWADRW) 11 Philadelphia 2009